Related Experiment Videos
Specific oncolytic activity of herpesvirus saimiri in pancreatic cancer cells
A J Stevenson1, M S Giles, K T Hall
1Molecular Medicine Unit, University of Leeds, St. James's University Hospital, UK.
Abstract:
The potential use of oncolytic viruses in the treatment of cancer has been investigated for some time. A variety of agents have been studied, including some which appear to be selectively replication-competent in cancer cell lines. In this study, we have investigated the ability of herpesvirus saimiri to specifically lyse selected human cancer cell lines. Upon infection with a replication-competent virus carrying the EGFP reporter gene and a neomycin resistance marker, the pancreatic cancer lines MIAPACA and PANC-1 exhibited definite cytopathic effects. In contrast, the colonic carcinoma cell lines SW480 and HCT116 were phenotypically unaltered. In addition, stable cell lines could not be generated from PANC-1 infected cultures, in marked contrast to cultures of cells from other human tissues. Virus recovery assays demonstrated that all of the cell lines produced a small amount of virus post-infection, but that virus replication was minimal after 1 week in culture. In addition, treatment with acyclovir inhibited virus replication but paradoxically increased cytopathic effect. These data suggest that herpesvirus saimiri may have potential as an oncolytic agent for the treatment of pancreatic cancer.
Insights
Herpesvirus saimiri shows potential as an oncolytic virus therapy for pancreatic cancer. This virus selectively caused cell death in pancreatic cancer lines, unlike colon cancer lines.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Oncolytic viruses are being explored for cancer treatment.
- Herpesvirus saimiri is being investigated for its selective cancer cell lysis capabilities.
Purpose of the Study:
- To evaluate the efficacy of herpesvirus saimiri as an oncolytic agent against human cancer cell lines.
- To determine the selectivity of herpesvirus saimiri for pancreatic cancer cells.
Main Methods:
- Infection of human cancer cell lines (MIAPACA, PANC-1, SW480, HCT116) with replication-competent herpesvirus saimiri.
- Assessment of cytopathic effects and virus replication post-infection.
- Evaluation of acyclovir's impact on virus replication and cytopathic effect.
Main Results:
- Herpesvirus saimiri induced significant cytopathic effects in pancreatic cancer cell lines (MIAPACA, PANC-1).
- Colonic carcinoma cell lines (SW480, HCT116) remained unaltered.
- Acyclovir treatment inhibited viral replication but enhanced cell lysis, suggesting complex interactions.
Conclusions:
- Herpesvirus saimiri demonstrates selective oncolytic potential against pancreatic cancer cells.
- Further research is warranted to explore herpesvirus saimiri as a targeted therapy for pancreatic cancer.